Loading
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Previous close
$1.02
−$0.02 · -1.92%
After-hours
$1.0378
+$0.0178 · +1.75%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Day range
Current $1.02
52-week range
Current $1.02
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
43
Fair Value
Sentiment
54
Mixed
Risk
71
High Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Day range
Current $1.02
52-week range
Current $1.02
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 33.03M USD | 38.63M USD | 41.29M USD | 44.26M USD | 33.89M USD |
| Cost of goods sold | 6.22M USD | 7.1M USD | 4.74M USD | 5.1M USD | 3.65M USD |
| Gross profit | 26.8M USD | 31.53M USD | 36.55M USD | 39.16M USD | 30.25M USD |
| Research and development | 20.82M USD | 22.23M USD | 23.82M USD | 19.51M USD | 15.41M USD |
| Selling, general, and administrative | 47.04M USD | 56.35M USD | 57.04M USD | 44.48M USD | 31.68M USD |
| Operating expenses | 72.09M USD | 82.72M USD | 84.85M USD | 66.52M USD | 48.44M USD |
| Interest income | 7.27M USD | 10.14M USD | 10.38M USD | 3.92M USD | 150.8K USD |
| Interest expense | — | — | — | 126.9K USD | 1.04M USD |
| Depreciation and amortization | 5.14M USD | 4.32M USD | 4.57M USD | 2.7M USD | 1.42M USD |
| Operating income | −45.29M USD | −51.2M USD | −48.3M USD | −27.36M USD | −18.19M USD |
| Net income | −44.63M USD | −41.06M USD | −37.92M USD | −23.57M USD | −19.08M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.00
488.24% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI3.54M0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF1.57M0.00%95.4B USD0.05%$233.13-0.15%
Vanguard Health Care ETFVHT366.59K0.00%22B USD0.09%$313.85-0.46%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM60K0.05%116.54M USD0.73%$15.90-0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Health Care ETFVHTEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
